Fosanis announced today that it closed a Series A funding round worth more than $10.5 million (€10 million). Berlin, Germany-based Fosanis, which develops prescription digital therapeutics for all oncological indications, picked up investments from existing shareholder Ananada Impact Ventures, as well as new investors Debiopharm Innovation Fund, Ship2B Ventures and Equity Pitcher. According to a […]